US-based biopharmaceutical company NovaRx will present the results from the Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer at the European Society for Medical Oncology (ESMO) ...
Tags: Novarx, Therapeutic Vaccine Trial